ADC Therapeutics SA ROE 2019-2022 | ADCT

Current and historical return on equity (ROE) values for ADC Therapeutics SA (ADCT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
ADC Therapeutics SA ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $-0.20B $0.16B -103.16%
2021-12-31 $-0.23B $0.17B -103.24%
2021-09-30 $-0.25B $0.19B -95.02%
2021-06-30 $-0.20B $0.24B -64.11%
2021-03-31 $-0.26B $0.30B -84.58%
2020-12-31 $-0.25B $0.34B -108.37%
2020-06-30 $-0.20B $0.20B -410.20%
2020-03-31 $-0.10B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00